- Home
- PESI vs CRVS Comparison
PESI vs CRVS Comparison
Compare PESI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- CRVS
- Stock Information
- Founded
- PESI 1990
- CRVS 2014
- Country
- PESI United States
- CRVS United States
- Employees
- PESI N/A
- CRVS N/A
- Industry
- PESI Environmental Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PESI Industrials
- CRVS Health Care
- Exchange
- PESI Nasdaq
- CRVS Nasdaq
- Market Cap
- PESI 153.6M
- CRVS 161.4M
- IPO Year
- PESI 1992
- CRVS 2016
- Fundamental
- Price
- PESI $9.72
- CRVS $4.03
- Analyst Decision
- PESI Strong Buy
- CRVS Buy
- Analyst Count
- PESI 1
- CRVS 3
- Target Price
- PESI $18.00
- CRVS $5.75
- AVG Volume (30 Days)
- PESI 86.6K
- CRVS 405.1K
- Earning Date
- PESI 10-31-2024
- CRVS 08-06-2024
- Dividend Yield
- PESI N/A
- CRVS N/A
- EPS Growth
- PESI N/A
- CRVS N/A
- EPS
- PESI N/A
- CRVS N/A
- Revenue
- PESI $72,199,000.00
- CRVS N/A
- Revenue This Year
- PESI N/A
- CRVS N/A
- Revenue Next Year
- PESI $60.84
- CRVS N/A
- P/E Ratio
- PESI N/A
- CRVS N/A
- Revenue Growth
- PESI N/A
- CRVS N/A
- 52 Week Low
- PESI $6.51
- CRVS $1.05
- 52 Week High
- PESI $14.17
- CRVS $4.75
- Technical
- Relative Strength Index (RSI)
- PESI 39.92
- CRVS 58.05
- Support Level
- PESI $10.53
- CRVS $3.90
- Resistance Level
- PESI $10.40
- CRVS $4.75
- Average True Range (ATR)
- PESI 0.51
- CRVS 0.30
- MACD
- PESI -0.12
- CRVS -0.08
- Stochastic Oscillator
- PESI 7.41
- CRVS 18.18
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: Treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).